This site is intended for health professionals only

At the heart of general practice since 1960

Ezetimibe no cancer risk

Treatment with ezetimibe does not increase a patient's risk of cancer, according to a major study of its use when prescribed in combination with a statin.

A previous study – the SEAS trial – had found ezetimibe was associated with an increase in new-onset cancers. But researchers from the University of Oxford analysed data from three trials, including SEAS, on 22,490 patients prescribed three different dose combinations of ezetimibe and simvastatin for a total mean follow-up period of 7.8 years.

The risk of cancer with ezetimibe was 0.96, indicating no effect on cancer incidence.

N Engl J Med 2008:359.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say